Cedric Tremblay, PhD

Research summary

Dr. Cedric Tremblay, an assistant professor at Max Rady College of Medicine and principal investigator at the Paul Albrechtsen Research Institute CancerCare Manitoba, focuses on deciphering molecular mechanisms underlying blood disorders and developing innovative therapeutic approaches.

His research employs bulk and single-cell multi-omic techniques to investigate how normal and malignant hematopoietic stem cells are regulated, with an emphasis on blood cancer, microenvironment interactions, and stem cell biology.

Research interests

• Blood cancer
• Microenvironment
• Stem cells

Research affiliations

Paul Albrechtsen Research Institute CancerCare Manitoba

Children’s Hospital Research Institute of Manitoba (CHRIM)

Dr. Cedric Tremblay serves as an assistant professor in the Department of Immunology and is a principal investigator at the Paul Albrechtsen Research Institute CancerCare Manitoba.

During his doctoral studies from 2004 to 2008, he delved into understanding the role of crucial regulatory signals from the hematopoietic niche in Fanconi Anemia—an inherited bone marrow failure syndrome associated with heightened cancer risk.

Following his doctoral studies, Dr. Tremblay continued his academic journey as a postdoctoral fellow at the University of Montréal, working under the guidance of Professor Trang Hoang. There, he focused on unraveling the mechanisms of oncogene collaboration in T-cell acute leukemia (T-ALL).

In 2011, he transitioned to the Australian Centre for Blood Diseases (ACBD), where he joined the Stem Cell Research Group led by Professor David Curtis. During his time at ACBD, Dr. Tremblay conducted research on the stem-cell-like properties of relapse-inducing cells in acute leukemia.

In 2022, Dr. Tremblay established his independent research group at the Paul Albrechtsen Research Institute CancerCare Manitoba and the University of Manitoba. With nearly two decades of experience in hematological diseases research, he has been at the forefront of investigating malignant stem cells in acute leukemia and testing novel therapeutics in pre-clinical models.